INVESTORS & MEDIA
Mar 8, 2023
Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas
Nov 14, 2022
Imugene’s onCARlytics combination with Estrella’s CD19-Redirected ARTEMIS® T Cells presented at SITC Annual Meeting
Oct 3, 2022
Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.